Frias Juan Pablo
a Department of Clinical Research , National Research Institute , Los Angeles , CA , USA.
Expert Rev Endocrinol Metab. 2019 Mar;14(2):75-83. doi: 10.1080/17446651.2019.1571908. Epub 2019 Feb 5.
Combining antihyperglycemic agents in order to rapidly and safely achieve the best possible glycemic control is the standard of care today for the management of type 2 diabetes. Agents should ideally have mechanisms of actions that are complementary and that improve glycemic control without unacceptable gain in body weight or hypoglycemia. Areas covered: Ertugliflozin and metformin hydrochloride (ertugliflozin/metformin, SEGLUROMET) is a recently approved fixed-dose combination tablet containing the sodium-glucose co-transporter 2 (SGLT-2) inhibitor ertugliflozin and metformin. This review summarizes key characteristics of ertugliflozin and metformin, as well as the efficacy and safety results of co-administration of these agents in the ertugliflozin clinical development program. This information comes from the ertugliflozin/metformin prescribing information as well as published clinical trials obtained through a PubMed search. Expert commentary: SGLT-2 inhibitors are an important class of antihyperglycemic agents that are efficacious as monotherapy and in combination with other antihyperglycemic agents. Given their favorable effects on glycemia control as well as 'extra-glycemic' parameters such as body weight and blood pressure, they are ideal agents for appropriate patients with type 2 diabetes. The fixed-dose combination of ertugliflozin with metformin is an effective combination that is conveniently administered and may improve medication adherence and persistence.
联合使用抗高血糖药物以快速、安全地实现最佳血糖控制是当今2型糖尿病管理的标准治疗方法。理想情况下，药物应具有互补的作用机制，能改善血糖控制，同时不会导致不可接受的体重增加或低血糖。涵盖领域：依鲁格列净和盐酸二甲双胍（依鲁格列净/二甲双胍，SEGLUROMET）是一种最近获批的固定剂量复方片剂，含有钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂依鲁格列净和二甲双胍。本综述总结了依鲁格列净和二甲双胍的关键特性，以及在依鲁格列净临床开发项目中联合使用这些药物的疗效和安全性结果。这些信息来自依鲁格列净/二甲双胍的处方信息以及通过PubMed搜索获得的已发表临床试验。专家评论：SGLT-2抑制剂是一类重要的抗高血糖药物，作为单药治疗以及与其他抗高血糖药物联合使用时均有效。鉴于它们对血糖控制以及体重和血压等“血糖外”参数具有有利影响，对于合适的2型糖尿病患者来说，它们是理想的药物。依鲁格列净与二甲双胍的固定剂量组合是一种有效的组合，给药方便，可能会提高药物依从性和持续性。
